Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

U.S. District Judge M. Casey Rodgers, accused in a misconduct complaint two weeks ago of showing preference to women, gave ...

Most medical devices in the United States come to market with limited clinical data, and device surveillance is viewed as a key way to keep patients safe. But the FDA’s system for collecting data and ...

John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.